The Preuss Foundation Interleukin-2/LAK Cell Treatment of Brain Tumors Seminar II
September 19, 1988
Dallas, Texas
David Barba, M.D.
National Institutes of Health, NINCDS
Bethesda, Maryland
Robert Dorsch, Ph.D.
DuPont Medical Products Department
Wilmington, Delaware
Gale A. "Morrie" Granger, Ph.D.
Department of Molecular Biology & Biochemistry
Irvine, California
Elizabeth A. Grimm, Ph.D.
University of Texas System Cancer Center
Houston, Texas
Ronald B. Herberman, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Marylou Ingram, M.D.
Huntington Medical Research Insitite
Pasadena, California
Paul L. Kornblith, M.D.
Albert Einstein College of Medicine
Bronx, New York
Carol A. Kruse, Ph.D.
University of Colorado
Denver, Colorado
Maria Kuppner, Ph.D.
University Hospital, Chuv
Lausanne, Switzerland
Daniel Levitt, M.D., Ph.D.
Hoffman-Laroche, Inc.
Nutley, New Jersey
Kevin O. Lillehei, M.D.
University of Colorado Health Science Center
Denver, Colorado
P. Juhani Linna, M.D.
E.I. du Pont de Nemours & Company
Wilmington, Delaware
M. Stephen Mahaley, Jr., M.D., Ph.D.
University of Alabama
Birmingham, Alabama
Randall E. Merchent, Ph.D.
Virginia Commonwealth University
Richmond, Virginia
Richard P. Moser, M.D.
M.D. Anderson Hospital and Tumor Institute
Houston, Texas
Carolyn Paradise, M.D.
Cetus, Inc.
Emeryville, California
David R. Parkinson, M.D.
University of Texas System Cancer Center
Houston, Texas
Stuart Ratner, Ph.D.
Michigan Cancer Foundation
Detroit, Michigan
Mark Rosenblum, M.D.
University of California, San Francisco
San Francisco, California
Stephen Saris, M.D.
National Institutes of Health, NINCDS
Bethesda, Maryland
Robert Selker, M.D.
University of Pittsburgh
Pittsburgh, Pennsylvania
Phillip Streeter, Ph.D.
Stanford University School of Medicine
Stanford, California
Richard Urban, Ph.D.
Cell Technology, Inc.
Boulder, Colorado
Harold F. Young, M.D.
Virginia Commonwealth University
Richmond, Virginia